logo

Passion for Innovation. Compassion for Patients.™

Daiichi Sankyo Europe GmbH

The Largest Antithrombotic Trials

ENGAGE AF-TIMI 48: ENGAGE AF-TIMI 48 is the largest (21,105 patients) and the longest (median follow-up duration of 2.8 years) trial to date for stroke prevention in atrial fibrillation1,2.

Hokusai-VTE: Hokusai VTE is the largest (8,292 patients) study to date of a non-vitamin K antagonist oral anticoagulant (NOAC) in venous thromboembolism (VTE) that studied patients with DVT and/or PE3,4.

TRITON TIMI 38: TRITON TIMI 38 (13,608 patients) is the largest trial to date evaluating a potent platelet inhibitor in ACS-PCI to prevent major cardiovascular events5.

 

Quality Assurance in Antithrombotic Clinical Trials

  • We know how essential it is for patients and healthcare professionals to have full confidence in our products. That’s why we evaluate new treatments to the highest ethical standards. Daiichi Sankyo products are only made available once they have been evaluated through robust and high quality clinical trials, including the largest in their respective fields.
  • That means our products are compared against standards of care, among a broad range of patients, including those most at risk.
  • We do this to reflect best clinical practice and assure healthcare professionals of the dosing, safety and efficacy when prescribing our products to their patients.

 

 

References

1. Giugliano RP, Ruff CT, Braunwald E, et al. ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093-2104.
2. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955-962.
3. Büller HR, Décousus H, Grosso MA, et al. Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(15):1406-1415.
4. Kang N, Sobieraj DM. Indirect treatment comparison of new oral anticoagulants for the treatment of acute venous thromboembolism. Thromb Res. 2014;133(6):1145-1151.
5. Wiviott, S, Braunwald, E, et al. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. NEJM. November 2007;357:2001-15.